The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is: · Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \> 100\*10\^9/L.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
30
Patients enrolled were administered Hetrombopag starting from +4d after transplantation on routine medication of recombinant human thrombopoietin injection (rhTPO). The starting dose of Hetrombopag is 2.5mg or 5mg, oral, once daily (starting at 5mg/d for body weight\>20kg; starting from 2.5mg/d for body weight ≤ 20kg). Adjust the dosage based on platelet count every two weeks, with a maximum dose of 7.5mg per day. Stop the medication after 6 weeks of continuous use or when PLT reaches 100 × 10\^9/L.
Department of Stem Cell Transplantation, Beijing Children's Hospital, Capital Medical University
Beijing, China
RECRUITINGAccumulated platelet engraftment rate
Platelet engraftment is defined as a continuous 7-day PLT ≥ 20 × 10\^9/L without platelet infusion.
Time frame: From enrollment to 60 days post-transplant
Number of platelet transfusions
Time frame: From enrollment to 60 days post-transplant
Time to platelet engraftment
Time frame: From enrollment to 60 days post-transplant
progression-free survival (PFS)
The time from enrollment to the first occurrence of disease progression or death from any cause
Time frame: From enrollment to 60 days post-transplant
Adverse events
Any adverse events within 30 days of discontinuation
Time frame: From medication to 30 days after discontinuation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.